GlassScriptPhysician profile
Steve H Jin
NPI 1760596985
$11,019.51
in general payments reported to CMS, 2019-2025
38 companies · $3,397 in 2025
The $3,397 reported for 2025 was more than what 77% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $342 · 2021: $588 · 2022: $1,291 · 2023: $1,092 · 2024: $3,564 · 2025: $3,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,205 · Travel and Lodging: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,204.57 |
| Travel and Lodging | $1,847.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,461.92 | 2019-2025 | Optis, Aveir, Dragonfly Opstar |
| Medtronic, INC. | $1,665.60 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Linq II |
| Penumbra, INC. | $1,124.44 | 2024-2025 | Indigo System |
| Abiomed | $966.43 | 2021-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $515.56 | 2019-2024 | Lifevest |
| Edwards Lifesciences Corporation | $499.38 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Shockwave Medical, INC | $325.43 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiva Medical, INC. | $234.33 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire |
| Impulse Dynamics (USA) INC. | $227.47 | 2022-2024 | Optimizer, Optimizer |
| Biosense Webster, INC. | $210.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $205.45 | 2019-2024 | |
| Chiesi USA, INC. | $199.41 | 2023-2025 | Kengreal, Cleviprex |
| Heartflow, INC. | $163.36 | 2025 | |
| Esperion Therapeutics, INC. | $138.78 | 2021-2025 | Nexletol |
| Silk Road Medical, INC. | $132.76 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.58 | 2020-2023 | |
| Amgen INC. | $102.84 | 2019-2024 | Repatha |
| Novo Nordisk INC | $92.87 | 2021-2025 | Wegovy, Ozempic |
| Cagent Vascular INC | $66.80 | 2024 | Serrantor |
| Cardiovascular Systems INC. | $55.68 | 2022 | |
| Angiodynamics, INC. | $49.53 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Amarin Pharma, INC. | $48.79 | 2021 | |
| Merck Sharp & Dohme LLC | $48.23 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $44.57 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $35.91 | 2020 | |
| Inari Medical, INC. | $35.46 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $34.33 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $27.79 | 2021-2025 | Crosser Iq |
| Boston Scientific Corporation | $27.08 | 2019 | |
| Ekos Corporation | $23.42 | 2019 | |
| Becton, Dickinson and Company | $22.86 | 2025 | Rotarexs 6 F X 135 Cm |
| Alnylam Pharmaceuticals INC. | $22.78 | 2025 | Amvuttra |
| Biotronik INC. | $18.99 | 2019 | |
| Cvrx, INC. | $18.93 | 2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $18.16 | 2024 | |
| Medtronic Vascular, INC. | $16.26 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.